This is fascinating but also a bit overwhelming. Is there a simple way to think about it? Like, GLP-1 makes you eat less, GIP makes the insulin work better, and glucagon makes you burn more? Am I oversimplifying?
That's actually a pretty solid simplification! I'd refine it slightly:
The magic is in the combination. Each component addresses a different facet of metabolic disease, and the potential downsides of each (GLP-1 nausea, GCG hyperglycemia) are buffered by the others. It's elegant pharmacology.
What I want to know is whether the tolerability is actually better. The Phase 2 trial had pretty significant GI side effects at the highest doses, especially early in titration. If the real-world dropout rate is high because people can't tolerate the nausea, the theoretical advantages don't matter much.
The slow titration schedule helped in the trial, but compliance in clinical practice is always worse than in controlled studies.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFair point. From the Phase 2 data, the discontinuation rate due to adverse events was about 6% across the retatrutide arms vs. 3% for placebo. That's actually comparable to tirzepatide's Phase 3 (SURMOUNT-1 had ~4.3% discontinuation in the 15mg arm).
The GI side effects (nausea, diarrhea, vomiting) were most prevalent during the first 4-8 weeks of titration and tended to resolve. This is consistent with the GLP-1 class generally. The glucagon component doesn't appear to add significant GI burden — its side effect profile is more about the metabolic effects (slight heart rate increase, transient glucose elevations during titration).